Evidence map›Paper›PMID 36189189›Full record

ArticleJournal of asthma and allergy2022

Utilization Patterns and Trends in the Use of Medications for Asthma in a Cohort of Colombian Patients.

Manuel Enrique Machado-Duque, Andrés Gaviria-Mendoza, Luis Fernando Valladales-Restrepo, Carmen García-Nuncira, María Laucho-Contreras, Jorge E Machado-Alba

Abstract read
In one paragraph

Article in Journal of asthma and allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cost-utility of tiotropium in patients with severe asthma.Cost effectiveness and resource allocation : C/E · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Manuel Enrique Machado-DuqueGrupo de Investigación en Farmacoepidemiologia y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A, Pereira, Colombia.ORCID 0000-0001-8458-0986
Andrés Gaviria-MendozaGrupo de Investigación en Farmacoepidemiologia y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A, Pereira, Colombia.ORCID 0000-0003-2500-7658
Luis Fernando Valladales-RestrepoGrupo de Investigación en Farmacoepidemiologia y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A, Pereira, Colombia.ORCID 0000-0002-4245-0101
Carmen García-NunciraGSK Colombia, Bogotá, Colombia.
María Laucho-ContrerasGSK Colombia, Bogotá, Colombia.
Jorge E Machado-AlbaGrupo de Investigación en Farmacoepidemiologia y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A, Pereira, Colombia.ORCID 0000-0002-8455-0936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Asthma affects approximately 358 million people worldwide. This study aimed to determine the trend for the use of medications intended to treat asthma in a group of patients affiliated with the Colombian health system. Patients and Methods: This was a retrospective study on prescription patterns of medications used to treat asthma in patients over 5 years of age between 2017 and 2019. Sociodemographic variables, medications used and combinations, the persistence of use, and prescribing physicians were considered. Data were obtained from a drug-dispensing database from Colombia. Results: A total of 10,706 people diagnosed with asthma were identified, including predominantly females (56.8%), with a mean age of 32.2 ± 26.1 years. At the beginning of the follow-up, 53.2% of patients aged 5-11 years were receiving monotherapy, with a mean of 1.5 ± 0.6 drugs/patient, especially inhaled corticosteroids (ICSs; 55.9%) and short-acting β-agonists (SABAs; 55.6%). Moreover, in patients older than 12 years, 53.5% were treated with monotherapy, with a mean of 1.6 ± 0.7 drugs/patient, 45.9% of whom were on SABAs, while 37.1% were on ICSs. Between 63.0% and 83.6% of patients were treated by a general practitioner. 12.5% of patients (n = 495) received triple therapy (ICS/LABA + LAMA [long-acting antimuscarinic]), particularly fluticasone/salmeterol + tiotropium. Conclusion: The identification of treatment patterns will allow physicians and decision makers to implement strategies in order to promote adherence to treatment and improve asthma medication use.

Indexed as

adrenergic beta-agonistsanti-asthma agentsasthmacholinergic antagonistscorticosteroidspharmacoepidemiology

Identifiers

PMID36189189
PMCPMC9522479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.